Published: Wed, May 24, 2017
Money | By Armando Alvarado

Should You Buy Calithera Biosciences, Inc. (NASDAQ:CALA) On Current Analyst Views?


CALA's SI was 743,100 shares in May as released by FINRA. Insiders own 0.60% of the company shares. Wellington Management Group LLP acquired a new stake in shares of Calithera Biosciences during the first quarter valued at about $47,550,000. Connor Clark Lunn Mngmt invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). (NASDAQ:CALA) was up +17.52% during the last trading session, with a day high of 16.20. About shares traded. Calithera Biosciences Inc (NASDAQ:CALA) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500. The stock, after opening at $16.3, hit $16.5 through the close by scoring 2.48%. D E Shaw & Incorporated owns 77,592 shares for 0% of their portfolio. The target implies a 89.93% spike from where the shares are now trading.

With all other things going on, Calithera Biosciences, Inc. The firm's market capitalization is $570.00 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It now has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Calithera Biosciences earned a media sentiment score of 0.26 on Alpha One's scale. Therefore 75% are positive. Citigroup Inc upgraded shares of Calithera Biosciences from a "sell" rating to a "neutral" rating and set a $5.00 target price for the company in a research report on Tuesday, January 24th. For the past month, Calithera Biosciences, Inc.'s stock has been 46.67%, 83.33% for the last quarter, 407.69% for the past six months and 275.85% for the past 52 weeks. First Eagle Invest Ltd Liability Corp has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Progenics Pharmaceuticals, Inc. has 4 buy ratings, 0 holds and 0 sells even after the stock tumbled -40.7% from its high of $11.72 to a $499.91 million market value through last close. The firm has "Market Outperform" rating given on Wednesday, March 9 by JMP Securities.

03/28/2017 - Calithera Biosciences, Inc. had its "buy" rating reiterated by analysts at H.C. Wainwright. HC Wainwright set a $10.00 target price on Calithera Biosciences and gave the stock a "buy" rating in a research note on Thursday, February 2nd.

The net percent change held by Institutional Investors has seen a change of 1.76% in last three month period. KCG Holdings Inc. acquired a new position in shares of Calithera Biosciences during the first quarter worth $144,000. 4 funds opened positions while 14 raised stakes. New York-based Goldman Sachs Gp has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Vanguard Grp Incorporated Inc holds 0% or 462,878 shares. Its down 7.69% from 1.95M shares, reported previously. Leerink Swann analyst J. Chang now expects that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their prior forecast of ($0.36). Rbf Capital Ltd Liability Com holds 0.01% or 13,000 shares. Manufacturers Life Insurance The accumulated 108 shares. California Employees Retirement Systems invested in 14,100 shares or 0% of the stock. Wells Fargo & Mn owns 8,520 shares or 0% of their U.S. portfolio.

Ariana Grande concert: MA musician OK after Manchester, England bombing
People were just pushing and pushing and pushing. "It was just. chaos", Sebastian Diaz, a 19-year-old from Newcastle, told AFP. A local newspaper has been overwhelmed with donations after setting up a fund for victims of the Manchester terror attack .

News coverage about Calithera Biosciences (NASDAQ:CALA) has been trending positive recently, according to Alpha One. 282.62 million shares or 3.33% more from 273.52 million shares in 2016Q3 were reported.

Annual earnings per share (EPS) growth noted at 12.60% in past 5 Years. Moreover, Adell Harriman And Carpenter has 0% invested in Plains All American Pipeline, L.P. (NYSE:PAA).

Volatility of the shares is also to be considered while making the investment decisions. First Trust invested in 0.17% or 38,443 shares. 65,211 were accumulated by Alliancebernstein L P. National Bank holds 9,874 shares or 0% of its portfolio.

Like this: